Clinical Trials Directory

Allogeneic Hematopoietic Cell Transplantation of Positively Selected CD34+ Cells and Defined Inoculum of T Cells From Related Haploidentical Donors for Older Patients With Indolent Hematologic Malignancies

The purpose of the study is to evaluate the feasibility and safety of transplanting CD34+ selected hematopoietic cells from a haploidentical related donor following a nonmyeloablative regimen of total lymphoid irradiation (TLI) and antithymocyte globulin (ATG).

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : Cyclosporine
  • drug : Anti-Thymocyte Globulin
  • drug : G-CSF
  • drug : Mycophenolate Mofetil
  • procedure : non-myeloablative hematopoietic cell transplantation

Phase: Phase 2


Ages Eligible For Study:

12 Months - 80 Years

Inclusion Criteria

- a haploidentical donor is available

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
BMT Referrals
Not Recruiting

Footer Links: